Bullish Moving Averages
15
Bearish Moving Averages
1
Products
Investments
Back Stocks profile
Today’s low
1508.20Today’s High
1534.9052W low
1028.8052W High
1638.80Open Price
1514.00Prev. Close
1472.7000Volume
1370020.00Value
2087978981.00Market Cap Cr
365670.70
Price to Earnings
38.20
Price to Book Value
5.40
Dividend Yield
0.80
PE to Growth
2.90
Op Revenue TTM Cr
48496.85
Net Profit TTM Cr
9576.38
Cash From Operating Activity Cr
12134.98
Return on Equity %
15.04
EMA & SMA
Bullish Moving Averages
15
Bearish Moving Averages
1
DELIVERY AND VOLUME
02 Jul, 2024
Week
Month
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
PIVOT
First Resistance
1536.55
Second Resistance
1549.05
Third Resistance
1563.20
First Support
1509.90
Second Support
1495.75
Third Support
1483.25
Relative Strength Index
55.98
Money Flow Index
61.55
MACD
4.39
MACD Signal
0.04
Average True Range
29.66
Average Directional Index
20.04
Rate of Change (21)
4.4
Rate of Change (125)
21.01
Commodity Channel Index
82.9
Williams %R
-19.1
BETA
1 Month
0.41
3 Month
0.48
1 Year
0.4
3 Year
0.12
PRICE CHANGE ANALYSIS
1 Week
Low
High
1492.3
1538.95
1 Month
Low
High
1377.2
1538.95
3 Months
Low
High
1377.2
1638.85
6 Months
Low
High
1257.15
1638.85
1 Year
Low
High
1028.75
1638.85
Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Qtr Revenue cr | 5758.02 | 5150.55 | 5202.75 | 4629.61 | 6068.52 | 4713.78 | 5327.00 | 4981.87 | 4307.29 | 4075.89 | 4427.42 | |
Operating Expenses Qtr | 3745.61 | 3714.75 | 3709.89 | 3517.31 | 3587.57 | 3646.37 | 3622.12 | 3483.22 | 3007.04 | 3114.27 | 3278.88 | |
Operating Profit Qtr | 1893.53 | 1359.00 | 1386.32 | 948.76 | 2360.65 | 999.38 | 1663.17 | 1449.66 | 999.84 | 656.39 | 864.27 | |
EBIDT Qtr Cr | 2012.41 | 1365.99 | 1492.86 | 963.09 | -456.84 | 1067.41 | 1704.88 | 1498.65 | -354.71 | 961.62 | 1148.54 | |
Depreciation Qtr | 393.04 | 399.60 | 392.71 | 415.27 | 411.98 | 430.44 | 383.95 | 374.50 | 354.14 | 355.24 | 333.64 | |
Net Profit Qtr | 867.60 | 721.31 | 888.63 | 380.64 | -1020.82 | 486.73 | 1213.01 | 1011.80 | -1286.21 | 515.43 | 809.07 | |
Basic EPS Qtr | 3.60 | 3.00 | 3.70 | 1.60 | -4.30 | 2.00 | 5.10 | 4.20 | -5.40 | 2.10 | 3.40 |
Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
---|---|---|---|---|---|---|
Total Revenue Annual | 20740.93 | 21091.17 | 16543.90 | 12953.43 | 14042.85 | |
Operating Expenses Annual Cr | 14687.56 | 14339.28 | 12678.46 | 9867.21 | 9820.28 | |
Operating Profit Annual | 5587.61 | 6472.86 | 2907.52 | 2936.00 | 2711.65 | |
Operating Profit Margin Annual % | 26.94 | 30.69 | 17.57 | 22.67 | 19.31 | |
Total Expenses Annual Cr | 17072.26 | 16412.33 | 14416.51 | 10711.00 | 10789.85 | |
EBIDT Annual Cr | 6053.37 | 6751.89 | 3865.44 | 3086.22 | 4222.57 | |
EBIDT Annual margin % | 29.19 | 32.01 | 23.36 | 23.83 | 30.07 | |
Depreciation | 1600.62 | 1600.87 | 1349.95 | 586.81 | 561.56 | |
PAT Before ExtraOrdinary Items Annual Cr | 2858.18 | 1690.72 | -99.99 | 2139.70 | 3211.14 | |
Net Profit Annual | 2858.18 | 1690.72 | -99.99 | 2139.70 | 3211.14 | |
Basic EPS Annual | 11.90 | 7.00 | -0.40 | 8.92 | 13.40 |
Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
---|---|---|---|---|---|---|
Total ShareHolders Funds Annual | 23694.40 | 23748.36 | 24587.95 | 25040.16 | 24396.22 | |
Minority Interest Liability Annual Cr | - | - | - | - | - | |
Total Non Current Liabilities Annual Cr | 12925.25 | 8873.07 | 6071.70 | 5615.12 | 2810.37 | |
Total Current Liabilities Annual Cr | 4445.14 | 8366.06 | 10105.83 | 8343.55 | 11203.74 | |
Total Capital Plus Liabilities Annual Cr | 41064.79 | 40987.49 | 40765.48 | 38998.83 | 38410.33 | |
Fixed Assets Annual | 8502.85 | 9564.58 | 10541.42 | 6007.15 | 5825.35 | |
Total Non Current Assets Annual | 26110.38 | 24522.34 | 31061.73 | 26932.49 | 26469.21 | |
Total Current Assets Annual | 14954.41 | 16465.15 | 9703.75 | 12066.34 | 11941.12 | |
Total Assets Annual | 41064.79 | 40987.49 | 40765.48 | 38998.83 | 38410.33 | |
Contingent Liabilities plus Commitments Annual Cr | - | 4309.60 | 3811.82 | 3564.25 | 3863.62 |
Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
---|---|---|---|---|---|---|
Cash from Operating Activity Annual | -292.42 | 507.08 | 7636.36 | 1737.25 | 1305.85 | |
Cash from Investing Activity Annual | -262.91 | -705.17 | -2702.10 | -601.80 | 1479.29 | |
Cash from Financing Annual Activity | 473.95 | 169.31 | -4870.85 | -1126.29 | -2871.15 | |
Net Cash Flow Annual | - | -28.78 | 63.41 | 9.16 | -86.01 |
Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
---|---|---|---|---|---|---|
Book Value Per Share Annual | 98.76 | 98.98 | 102.48 | 104.36 | 101.68 | |
ROE Annual % | 12.06 | 7.11 | -0.40 | 8.54 | 13.16 | |
ROCE Annual % | 12.15 | 15.79 | 8.20 | 8.15 | 13.45 | |
Total Debt to Total Equity Annual | 0.47 | 0.32 | 0.20 | 0.26 | 0.24 | |
EBDIT Annual Margin % | 29.85 | 32.44 | 24.80 | 24.10 | 33.69 |
Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Qtr Revenue cr | 12588.84 | 12630.90 | 12486.02 | 12145.28 | 11303.95 | 11414.85 | 11037.50 | 10763.90 | 9560.35 | 10295.57 | 9848.82 | |
Operating Expenses Qtr | 8947.75 | 8903.87 | 9013.03 | 8609.07 | 8128.54 | 8237.25 | 7995.73 | 7877.37 | 7106.39 | 7256.73 | 6995.99 | |
Operating Profit Qtr | 3035.15 | 3476.83 | 3179.38 | 3331.77 | 2802.13 | 3003.72 | 2956.55 | 2884.39 | 2340.37 | 2606.33 | 2629.94 | |
EBIDT Qtr Cr | 3539.45 | 3657.22 | 3472.99 | 3213.34 | 3003.96 | 3177.60 | 3041.77 | 2886.53 | -1481.79 | 3038.84 | 2852.83 | |
Depreciation Qtr | 650.36 | 622.14 | 632.82 | 651.32 | 671.53 | 659.95 | 609.95 | 588.00 | 556.47 | 553.68 | 530.37 | |
Net Profit Qtr | 2654.58 | 2523.75 | 2375.51 | 2022.54 | 1984.47 | 2166.01 | 2262.22 | 2060.88 | -2277.25 | 2058.80 | 2047.01 | |
Basic EPS Qtr | 11.10 | 10.50 | 9.90 | 8.40 | 8.30 | 9.00 | 9.40 | 8.60 | -9.50 | 8.60 | 8.50 |
Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
---|---|---|---|---|---|---|
Total Revenue Annual | 49851.04 | 44520.20 | 39576.00 | 34333.66 | 33473.48 | |
Operating Expenses Annual Cr | 35473.72 | 32238.89 | 28256.77 | 25006.77 | 25847.74 | |
Operating Profit Annual | 13023.13 | 11646.79 | 10397.72 | 8491.37 | 6989.76 | |
Operating Profit Margin Annual % | 26.12 | 26.16 | 26.27 | 24.73 | 20.88 | |
Total Expenses Annual Cr | 38268.83 | 34940.32 | 30527.86 | 27228.15 | 28203.25 | |
EBIDT Annual Cr | 14377.32 | 12281.31 | 11319.23 | 9326.89 | 7625.74 | |
EBIDT Annual margin % | 28.84 | 27.59 | 28.60 | 27.17 | 22.78 | |
Depreciation | 2556.64 | 2529.43 | 2143.74 | 2079.95 | 2052.78 | |
PAT Before ExtraOrdinary Items Annual Cr | 9648.44 | 8560.84 | 3405.82 | 2284.68 | 4186.79 | |
Net Profit Annual | 9576.38 | 8473.58 | 3272.73 | 2903.82 | 3764.93 | |
Basic EPS Annual | 39.90 | 35.30 | 13.60 | 12.10 | 15.70 |
Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
---|---|---|---|---|---|---|
Total ShareHolders Funds Annual | 63666.75 | 55995.38 | 48011.22 | 46462.78 | 45264.45 | |
Minority Interest Liability Annual Cr | 3439.22 | 3320.09 | 3054.89 | 3017.05 | 3860.24 | |
Total Non Current Liabilities Annual Cr | 1372.51 | 1521.12 | 1533.21 | 2041.27 | 3421.34 | |
Total Current Liabilities Annual Cr | 16984.40 | 19907.00 | 17200.55 | 16145.63 | 15706.43 | |
Total Capital Plus Liabilities Annual Cr | 85462.88 | 80743.59 | 69799.87 | 67666.73 | 68252.46 | |
Fixed Assets Annual | 19966.31 | 20680.57 | 17197.09 | 16832.17 | 17585.79 | |
Total Non Current Assets Annual | 41987.90 | 40860.25 | 34784.89 | 37224.65 | 36598.30 | |
Total Current Assets Annual | 43474.98 | 39883.34 | 35014.98 | 30442.08 | 31654.16 | |
Total Assets Annual | 85462.88 | 80743.59 | 69799.87 | 67666.73 | 68252.46 | |
Contingent Liabilities plus Commitments Annual Cr | - | 7903.07 | 6756.55 | 7057.73 | 7508.95 |
Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
---|---|---|---|---|---|---|
Cash from Operating Activity Annual | 12134.98 | 4959.33 | 8984.54 | 6170.37 | 6554.77 | |
Cash from Investing Activity Annual | -690.20 | -7943.68 | -5724.74 | 536.22 | -2588.84 | |
Cash from Financing Annual Activity | -6710.16 | 2376.07 | -5193.46 | -5980.48 | -5715.14 | |
Net Cash Flow Annual | - | -608.28 | -1933.66 | 726.11 | -1749.21 |
Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
---|---|---|---|---|---|---|
Book Value Per Share Annual | 279.69 | 247.22 | 212.84 | 206.23 | 204.75 | |
ROE Annual % | 15.04 | 15.13 | 6.81 | 6.24 | 8.31 | |
ROCE Annual % | 17.26 | 16.02 | 17.44 | 14.06 | 10.60 | |
Total Debt to Total Equity Annual | 0.04 | 0.11 | 0.02 | 0.07 | 0.17 | |
EBDIT Annual Margin % | 29.64 | 27.98 | 29.28 | 27.84 | 23.22 |
Name | Holding Percent | Holding Id | Pledged % | Locked % |
---|---|---|---|---|
Icici Prudential Value Discovery Fund | 3.15 | 75037419 | - | - |
Nps Trust- A/C Sbi Pension Fund Scheme - State Govt | 1.17 | 75037424 | - | - |
Government Pension Fund Global | 1.04 | 75037429 | - | - |
Name | Holding Percent | Holding Id | Pledged % | Locked % |
---|---|---|---|---|
Dilip. S. Shanghvi | 9.6 | 75037402 | 0 | 0 |
Sudhir V. Valia | 0.6 | 75037403 | 0 | 0 |
Shanghvi Finance Private Limited | 40.3 | 75037409 | 0 | 0 |
Aditya Medisales Limited | 1.67 | 75037410 | 0.02 | 0 |
Raksha S.Valia | 1.2 | 75037411 | 92.58 | 0 |
Name | Holding Percent | Holding Id |
---|---|---|
Icici Prudential Value Discovery Fund | 3.15 | 75037419 |
Sbi Nifty 50 Etf | 2.27 | 75037420 |
Government Pension Fund Global | 1.04 | 75037429 |
Life Insurance Corporation Of India | 2.92 | 75037422 |
Nps Trust- A/C Sbi Pension Fund Scheme - State Govt | 1.17 | 75037424 |
Name | Holding Percent | Holding Id |
---|
Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
---|---|---|---|---|
Jul 12, 2024 | 5 | FINAL | Jul 12, 2024 | Equity Share |
Feb 09, 2024 | 8.5 | INTERIM | Feb 09, 2024 | Equity Share |
Jul 28, 2023 | 4 | FINAL | Jul 28, 2023 | Equity Share |
Feb 08, 2023 | 7.5 | INTERIM | Feb 08, 2023 | Equity Share |
Aug 19, 2022 | 3 | FINAL | Aug 22, 2022 | Equity Share |
Feb 09, 2022 | 7 | INTERIM | Feb 10, 2022 | Equity Share |
Aug 23, 2021 | 2 | FINAL | - | Equity Share |
Feb 09, 2021 | 5.5 | INTERIM | Feb 10, 2021 | Equity Share |
Aug 19, 2020 | 1 | FINAL | - | Equity Share |
Feb 17, 2020 | 3 | INTERIM | Feb 18, 2020 | Equity Share |
Aug 20, 2019 | 2.75 | FINAL | - | Equity Share |
Sep 17, 2018 | 2 | FINAL | - | Equity Share |
Sep 18, 2017 | 3.5 | FINAL | - | Equity Share |
Sep 08, 2016 | 1 | FINAL | - | Equity Share |
Oct 21, 2015 | 3 | FINAL | - | Equity Share |
Sep 11, 2014 | 1.5 | FINAL | - | Equity Share |
Sep 19, 2013 | 2.5 | FINAL | - | Equity Share |
Aug 14, 2012 | 4.25 | INTERIM | Aug 16, 2012 | Equity Share |
Sep 02, 2011 | 3.5 | FINAL | - | Equity Share |
Sep 09, 2010 | 13.75 | FINAL | - | Equity Share |
Aug 21, 2009 | 13.75 | FINAL | - | Equity Share |
Aug 25, 2008 | 10.5 | FINAL | - | Equity Share |
Mar 15, 2007 | 6.75 | INTERIM | Mar 16, 2007 | Equity Share |
Sep 06, 2006 | 5.5 | FINAL | - | Equity Share |
Sep 19, 2005 | 3.75 | FINAL | - | Equity Share |
Dec 10, 2004 | 3.25 | INTERIM | - | Equity Share |
Sep 24, 2003 | 5 | FINAL | - | Equity Share |
Oct 07, 2002 | - | FINAL | - | Equity Share |
Aug 20, 2002 | 5 | FINAL | - | Equity Share |
Jul 17, 2001 | - | INTERIM | Aug 01, 2001 | Equity Share |
Ex-Date | Split Ratio | Record Date |
---|---|---|
Nov 25, 2010 | 5:1 | 2010-11-26 |
Jan 13, 2003 | 10:5 | 2003-01-21 |
Ex-Date | Purpose | Notes |
---|---|---|
May 22, 2024 | Audited Results & Final Dividend | - |
Jan 31, 2024 | Quarterly Results & Interim Dividend | - |
Nov 01, 2023 | Quarterly Results | - |
Aug 03, 2023 | Quarterly Results | - |
May 26, 2023 | Audited Results & Final Dividend | - |
Jan 31, 2023 | Quarterly Results & Interim Dividend | - |
Nov 01, 2022 | Quarterly Results | - |
Jul 29, 2022 | Quarterly Results | - |
May 30, 2022 | Audited Results & Final Dividend | - |
Jan 31, 2022 | Quarterly Results & Interim Dividend | - |
Nov 02, 2021 | Quarterly Results | - |
Jul 30, 2021 | Quarterly Results | - |
May 27, 2021 | Audited Results & Final Dividend | - |
Jan 29, 2021 | Quarterly Results | - |
Nov 03, 2020 | Quarterly Results | - |
Jul 31, 2020 | Quarterly Results | - |
May 27, 2020 | Audited Results & Final Dividend | - |
Mar 17, 2020 | Buy Back of Shares | - |
Feb 06, 2020 | Quarterly Results | - |
Nov 07, 2019 | Quarterly Results | - |
Aug 13, 2019 | Quarterly Results | - |
May 28, 2019 | Audited Results & Dividend | - |
Feb 12, 2019 | Quarterly Results | - |
Nov 13, 2018 | Quarterly Results | - |
Aug 14, 2018 | Quarterly Results | - |
May 25, 2018 | Audited Results & Dividend | - |
Feb 14, 2018 | Quarterly Results | - |
Nov 14, 2017 | Quarterly Results | - |
May 26, 2017 | Audited Results & Dividend | - |
Feb 14, 2017 | Quarterly Results | - |
Nov 10, 2016 | Quarterly Results & Others | To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited. |
Aug 12, 2016 | Quarterly Results | - |
Jun 23, 2016 | Buy Back of Equity Shares | - |
May 30, 2016 | Audited Results & Dividend | - |
Feb 12, 2016 | Quarterly Results | - |
Nov 07, 2015 | Quarterly Results | - |
Aug 11, 2015 | Quarterly Results & Dividend | Consideration of the revised audited annual accounts of the Co for the year ended 31/03/ 2015 after giving the effect to the Scheme of Amalgamation of SPGI into SPIL. |
May 29, 2015 | Audited Results & Amalgamation | - |
Feb 14, 2015 | Quarterly Results | - |
Nov 13, 2014 | Quarterly Results | - |
Aug 12, 2014 | Revised Audited, Qtr Results & Dividend | Consider the revised audited annual accounts of the Co. for the year ended March 31, 2014 after giving the effect to the Scheme of Arrangement and Reconstruction between between SPIL and SPGFZE. |
May 29, 2014 | Audited Results | - |
Feb 13, 2014 | Quarterly Results | - |
Nov 13, 2013 | Quarterly Results | - |
Aug 09, 2013 | Quarterly Results | - |
May 28, 2013 | Others | - |
Feb 08, 2013 | Quarterly Results | - |
Nov 08, 2012 | Quarterly Results | - |
Aug 10, 2012 | Interim dividend & Others | To consider the internal restructuring of the business of the Company with effect from March 31,2012 & to consider declaration of the interim dividend of Rs.4.25 per Share of Re.1 each. |
May 29, 2012 | Audited Results & Dividend | - |
Feb 13, 2012 | Quarterly Results | - |
Nov 13, 2011 | Quarterly Results | - |
Jul 28, 2011 | Quarterly Results | - |
May 28, 2011 | Audited Results & Dividend | - |
Jan 31, 2011 | Quarterly Results | - |
Oct 30, 2010 | Quarterly Results | - |
Sep 24, 2010 | Stock split | The Board has approved the proposal to sub-divide the nominal value of the Equity Shares of the Company from the nominal value of Rs. 5 each to the nominal value of Re. 1 each. |
Jul 28, 2010 | Quarterly Results | - |
May 24, 2010 | Audited Results & Dividend | - |
Jan 29, 2010 | Quarterly Results | - |
Oct 28, 2009 | Quarterly Results | - |
Jul 29, 2009 | Quarterly Results | - |
May 30, 2009 | Audited Results & Dividend | - |
Jan 30, 2009 | Quarterly Results | - |
Oct 25, 2008 | Quarterly Results | - |
Jul 28, 2008 | Quarterly Results | - |
May 30, 2008 | Audited Results & Dividend | - |
Jan 30, 2008 | Quarterly Results | - |
Oct 25, 2007 | Quarterly Results & Others | To consider payment of interim dividend @ 6% p.a. on outstanding 1,37,40,030 Preference Shares of Re 1/- each on prorata basis for the period from April 01, 2007 to November 01, 2007. |
Jul 23, 2007 | Quarterly Results | - |
May 18, 2007 | Audited Results | (Revised) |
Mar 10, 2007 | Interim Dividend | - |
Jan 29, 2007 | Quarterly Results | - |
Oct 19, 2006 | Quarterly Results | - |
Jul 26, 2006 | Quarterly Results | - |
Jun 06, 2006 | Accounts & Dividend | Recommendation of payment of preference share dividend @ 6% p.a. on outstanding Preference Shares for the year ended March 31, 2006. |
Feb 09, 2006 | Demerger | inter alia, to consider the proposal for demerger of the Company's Innovative Research & Development (including new drug delivery systems) undertaking to a new company. |
Jan 30, 2006 | Quarterly Results | - |
Oct 28, 2005 | Quarterly Results | - |
Aug 18, 2005 | Accounts & Dividend | - |
Jul 27, 2005 | Quarterly Results | - |
Apr 27, 2005 | Quarterly Results | - |
Apr 04, 2005 | Acquisition of pharmaceutical business | Decided to acquire pharmaceutical business of M J Pharmaceuticals Ltd including its manufacturing unit at Halol, Gujarat along with all its assets and liabilities pertaining to pharmaceutical business |
Feb 08, 2005 | Merger/Amalgamation | To consider the proposal for merger / amalgamation of its wholly owned subsidiary companies (1) Bazley Finvest Pvt Ltd, (2) Dhaval Finvest Pvt Ltd and (3) Manish Finvest Pvt Ltd, with the Company. |
Jan 21, 2005 | Quarterly Results | - |
Nov 26, 2004 | Interim Dividend & Others | Issued US$ 275,000,000 Zero Coupon Foreign Currency Convertible Bonds (FCCB) due 2009 (subject to an increase of up to a further US$ 75,000,000 pursuant to the Option). |
Oct 21, 2004 | Quarterly Results | - |
Jul 31, 2004 | Quarterly Results | - |
Apr 21, 2004 | Dividend | - |
Apr 08, 2004 | Others | To consider the issue of convertible debentures/bonds/securities through global depository receipts. |
Jan 28, 2004 | Quarterly Results | - |
Oct 21, 2003 | Quarterly Results | (Revised) |
Sep 30, 2003 | Others | To consider early closure of Buy Back programme of the Company through the Stock Exchange route before its normal validity period. |
Jul 28, 2003 | Quarterly Results | - |
May 03, 2003 | Dividend & Accounts | - |
Jan 30, 2003 | Quarterly Results | - |
Dec 20, 2002 | Others | Fix record date for stock split of shares. |
Oct 28, 2002 | Stock Split, Quarterly Results & Others | from Rs.10/- each to Rs.5/- & & Buy Back of Shares |
Jul 22, 2002 | Quarterly Results | - |
Jun 28, 2002 | Others | To issue of Bonus Preference Shares to the equity shareholders |
May 30, 2002 | Accounts, Dividend & Others | To take on record BIFR order regarding merger of M.J.Pharmaceuticals Ltd. after its restructuring and to fix record date for merger & Dividend & Accounts |
Apr 26, 2002 | Quarterly Results | - |
Mar 21, 2002 | Interim Dividend | (Cancelled) |
Feb 15, 2002 | Accounts | To approve the annual accounts incorporationg PDCL merger for the year ended 31/03/2001. |
Jan 22, 2002 | Quarterly Results | - |
Nov 28, 2001 | Others | Interim dividend on Redeemable Cumulative Non-convertible Preference Shares issued by the Company. |
Oct 19, 2001 | Quarterly Results | - |
Jul 30, 2001 | Interim Dividend & Quarterly Results | - |
Apr 19, 2001 | Quarterly Results | - |
Mar 22, 2001 | Merger | Merger/Amalgamation of Sun Pharmaceutical Advanced Research Centre Ltd. with the Company, Interim Dividend on preference shares and Forfeiture of 500 partly paid equity shares |
Feb 26, 2001 | Others | To appoint M/s. Price Waterhouse C.A., Mumbai as a valuers to determine exchange ratio for merger of Pradeep Drug Co. Ltd. and approve draft scheme of amalgamation/merger. |
Feb 17, 2001 | Others | Amalgamation of Pradeep Drug Co. Ltd. with the Company |
Jan 16, 2001 | Quarterly Results | - |
Oct 18, 2000 | Quarterly Results | - |
Jul 17, 2000 | Quarterly Results | - |
Jun 06, 2000 | Accounts | - |
Apr 28, 2000 | Quarterly Results | - |
Apr 08, 2000 | Merger/amalgamation | - |
Apr 01, 2000 | Merger/Amalgamation | - |
Mar 18, 2000 | 2nd Interim Dividend | - |
Feb 01, 2000 | Issue of bonus shares | - |
Jan 15, 2000 | Quarterly Results | - |
Nov 06, 1999 | Interim Dividend | - |
Oct 28, 1999 | Quarterly Results, Accounts & Dividend | - |
Oct 27, 1999 | Quarterly Results | - |
Jul 15, 1999 | Quarterly Results | - |
Apr 29, 1999 | Quarterly Results | - |
Dec 03, 1998 | Others | - |
Nov 26, 1998 | Amalgamation & Merger | - |
Nov 13, 1998 | Pvt. Placements | - |
Oct 29, 1998 | Quarterly Results | - |
Sep 25, 1998 | Increase in Capital | - |
Jul 24, 1998 | Quaterly Results | - |
Apr 18, 1998 | Accounts & Dividend | - |
Feb 07, 1998 | To consider allotment of equity shares | - |
Nov 29, 1997 | Half Yearly Results | - |
Oct 21, 1997 | Half Yearly Results. | - |
May 29, 1997 | Amalgamation | - |
Apr 30, 1997 | Accounts & Dividend. | - |
Ex-Date | Bonus Ratio | Record Date |
---|---|---|
Jul 29, 2013 | 1:1 | 2013-07-30 |
May 27, 2004 | 1:1 | 2004-05-29 |
Mar 06, 2000 | 2:1 | 2000-03-23 |
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation regarding order passed by Statutory AuthoritySUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issuance of Letter of Confirmation.SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation regarding Statutory order passed by GST Authority.SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation regarding newspaper publicationSUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
Intimation regarding closure of trading window.Sun Pharma Finalises Acquisition Of Taro For $347.73 Million
Taro has become a privately held company and is now a wholly owned subsidiary of Sun Pharma.SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Intimation regarding completion of acquisition of all outstanding shares of TAROOutperformance of private sector banks may continue for next one year: Sandip Sabharwal
The smaller pharma companies I find it tough to evaluate, so many of them can potentially do well but I do not have the bandwidth to go molecule by molecule and evaluate those companies. But I think Sun Pharma is a decent business model, so we are just holding it for the long term.Sun Pharma's investigational weight loss drug shows promise in reducing obesity
The study enrolled 24 obese male participants who were divided into two groups: one with a fixed dosage and the other with increasing dosages of GL0034. The drug not only led to significant weight loss but also enhanced insulin sensitivity and reduced glucose levels.SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma''s GL0034 demonstrates a significant Phase 1 result in an oral presentation at ADA 84th scientific sessions.The latest market price of Sun Pharmaceutical Industries Ltd. on NSE was Rs. 1524.05 as of today.
The opening share price of Sun Pharmaceutical Industries Ltd. was Rs. 1514.00 as of today.
The 52-week high share price of Sun Pharmaceutical Industries Ltd. was Rs. 1638.80.
The 52 week low share price of Sun Pharmaceutical Industries Ltd. was Rs. 1028.80.
Sun Pharmaceutical Industries Ltd. has a market cap of Rs. 365670.70 crore as of today. Please refer to the Fundamentals section for further details.
The PE ratio of Sun Pharmaceutical Industries Ltd. is 2.90. Please refer to the Fundamentals section for further details.
The operating revenue for Sun Pharmaceutical Industries Ltd. in the last FY was Rs. 48496.85 crore. Please refer to the Financials section for further details.
The Net Profit for Sun Pharmaceutical Industries Ltd. in the last FY was Rs. 9576.38 crore. Please refer to the Financials section for further details.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
The latest dividend declared by Sun Pharmaceutical Industries Ltd. was on 2024-07-12 for Rs. 5 per share. According to today’s share price, the dividend yield of Sun Pharmaceutical Industries Ltd. stands at 0.80. Please refer to the Corporate Actions section for further details.
The latest bonus issue declared by Sun Pharmaceutical Industries Ltd. was as of 2013-07-29. The bonus ratio declared in this issue was 1:1. Please refer to the Corporate Actions section for further details.
The latest split issue declared by Sun Pharmaceutical Industries Ltd. was as of 2003-01-13. The split ratio declared in this issue was 10:5. Please refer to the Corporate Actions section for further details.
Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.
Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.
Please refer to the News section for the latest news about Sun Pharmaceutical Industries Ltd..